UMIN ID: UMIN000050007
Registered date:13/01/2023
Verification study on the effects of intake of test foods on the improvement quality of sleep
Basic Information
Recruitment status | Complete: follow-up complete |
---|---|
Health condition(s) or Problem(s) studied | Not applicable |
Date of first enrollment | 2023/01/13 |
Target sample size | 40 |
Countries of recruitment | Japan |
Study type | Interventional |
Intervention(s) | Daily intake of test food for 4 weeks Daily intake of placebo (control food) for 4 weeks |
Outcome(s)
Primary Outcome | Check for "Sleepiness on rising" in the OSA sleep inventory MA version (OSA-MA) |
---|---|
Secondary Outcome | "Initiation and maintenance of sleep" , "frequent dreaming", "refreshing", "sleep length" in the OSA-MA, PSQI, JESS, The sleep scope (Electroencephalogram (Initiation of sleep, Nocturnal awakening, Sleep efficiency), Sleep stage(REM/non-REM sleep)), The proportion of division or family of intestinal bacteria |
Key inclusion & exclusion criteria
Age minimum | 20years-old |
---|---|
Age maximum | Not applicable |
Gender | Male and Female |
Include criteria | |
Exclude criteria | (1) Persons who are on treatment for a serious illness. (2) Persons whose sleep time or sleep habits are irregular because of night shift etc. (3) Persons who visit the hospital because of mental disorders (depression etc.) or sleep disorders, or were diagnosed with mental disorders at once. (4) Persons who are diagnosed Sleep Apnea Syndrome or have subjective symptoms of apnea. (5) Subjects who select "I would like to kill myself." or "I would kill myself if I had the chance." at question 9 of Beck Depression Inventory-II (BDI2) at the screening test. (6) Habitual Smokers. (7) Persons who have metal Allergy or sensitive skin. (8) Persons who may be prevented from sound sleep by the other, for instance, who have preschoolers, who nurse care, who sleep on the bed two or more. (9) Persons with food allergies or those who may be allergic to the test food. (10) Persons who regularly use licensed drugs or quasi-drugs that may affect the study. (11) Persons who regularly use health foods that may affect the study. (12) Persons who are participating in a clinical trial or have participated in another clinical trial within 3 months from the date of obtaining consent. (13) Persons unable to maintain daily routines. (14) Pregnant, lactating, or wishing to become pregnant. (15) Persons who plan to participate in other examinations during the study. (16) Other subjects who are deemed inappropriate for this study by the investigator. |
Related Information
Primary Sponsor | APO PLUS STATION CO., LTD. |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | NISSIN YORK CO.,LTD. |
Secondary ID(s) |
Contact
public contact | |
Name | Yoshimura Hiroki |
Address | 2-14-1,Nihonbashi,Chuo-ku,Tokyo 103-0027, JAPAN Japan 103-0027 |
Telephone | 03-6386-8809 |
food-contact@apoplus.co.jp | |
Affiliation | Apoplus Station Co.,Ltd. CRO Department Clinical Operations Division |
scientific contact | |
Name | Segawa Shuichi |
Address | 272, Tsutsumine, Kamimurakimi, Hanyu-shi, Saitama, Japan Japan |
Telephone | 048-565-4686 |
shuichi.segawa@nissin.com | |
Affiliation | Nissin York Co., Ltd. Development Laboratories |